Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration.
Phase of Trial: Phase III
Latest Information Update: 16 Dec 2014
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Diabetic macular oedema; Wet macular degeneration
- Focus Biomarker; Therapeutic Use
- 19 Jun 2012 Actual initiation date (Nov 2011) added and planned patient number is 40 as reported by ClinicalTrials.gov.
- 19 Jun 2012 Planned end date (Jan 2014) added as reported by ClinicalTrials.gov.
- 22 Nov 2011 New trial record